Alterity Therapeutics Ltd (ATHE) shareholders
Close on Nov 16, 2026Market cap $35.53MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of ATHE | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Twin Lakes Capital Management, LLC | 139,258 | – | $747.82K | – | 0.29% |
| Morgan Stanley | 63,065 | – | $338.66K | +4,683 | 0.00% |
| Greenleaf Trust | 62,000 | – | $332.94K | +30,000 | 0.00% |
| HB Wealth Management, LLC | 58,460 | – | $313.93K | – | 0.00% |
| Citadel Advisors LLC | 37,597 | – | $201.90K | +17,520 | 0.00% |
| Hrt Financial LP | 17,292 | – | $92.00K | New | 0.00% |
| Bnp Paribas Arbitrage, Snc | 10,239 | – | $54.98K | +3,430 | 0.00% |
| GAMMA Investing LLC | 2,309 | – | $12.40K | +453 | 0.00% |
| Rhumbline Advisers | 2,009 | – | $10.79K | +39 | 0.00% |
| Acadian Asset Management LLC | 1,863 | – | $10.00K | – | 0.00% |
| Providence Capital Advisors, LLC | 200 | – | $1.07K | New | 0.00% |
| Integrated Wealth Concepts LLC | 73 | – | $392 | New | 0.00% |
| Osaic Holdings, Inc. | 68 | – | $362 | – | 0.00% |
| Ronald Blue Trust, Inc. | 40 | – | $215 | – | 0.00% |
| Farther Finance Advisors, LLC | 39 | – | $205 | +17 | 0.00% |
| CoreCap Advisors, LLC | 21 | – | $113 | – | 0.00% |
| Steward Partners Investment Advisory, LLC | 6 | – | $32 | – | 0.00% |
| UBS Group AG | 5 | – | $27 | New | 0.00% |
| Danske Bank A/S | 1 | – | $5 | – | 0.00% |
| Cranbrook Wealth Management, LLC | 1 | – | $6 | New | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|
| Q2 2026 | 22 | 0M | 7 / 7 | 0 / 0 | 0M | 0M |
| Q1 2026 | 15 | 0M | 0 / 2 | 5 / 2 | 0M | 0M |
| Q4 2025 | 18 | 0M | 4 / 1 | 5 / 2 | 0M | 0M |
| Q3 2025 | 16 | 0M | 6 / 4 | 2 / 1 | 0M | 0M |
| Q2 2025 | 11 | 0M | 2 / 1 | 1 / 3 | 0M | 0M |
| Q1 2025 | 12 | 0M | 2 / 4 | 1 / 2 | 0M | 0M |
| Q4 2024 | 13 | 0M | 3 / 2 | 2 / 3 | 0M | 0M |
| Q3 2024 | 13 | 0M | 4 / 1 | 2 / 1 | 0M | 0M |
| Q2 2024 | 10 | 0M | 2 / 0 | 1 / 2 | 0M | 0M |
| Q1 2024 | 10 | 0M | 4 / 1 | 0 / 2 | 0M | 0M |
| Q4 2023 | 9 | 0M | 3 / 1 | 0 / 1 | 0M | 0M |
| Q3 2023 | 7 | 0M | 1 / 0 | 1 / 1 | 0M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
2 funds held ATHE in Q1 2026, 0% of their shares through ETFs. Each fund counts once per quarter, from its quarter-end report.
| Fund | Shares | % of ATHE | Value | % of fund | As of |
|---|---|---|---|---|---|
| Fidelity Nasdaq Composite Index Fund | 1,155 | – | $4.76K | 0.00% | May 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | Latest filing |
|---|---|---|---|
| David Allen Stamler | Chief Executive Officer, Director | 11,827,570 | Sep 8, 2026 |
| Niven Abby Sarah Macnish | Chief Financial Officer | 454,545 | Apr 9, 2026 |
| Peter Ashley Marks | Director | 191,340 | Sep 8, 2026 |
| Lawrence Bernard Gozlan | Director | 4,545,455 | Jun 23, 2026 |
| Julian Michael Babarczy | Director | – | Jun 23, 2026 |
| Ann Michelle Cunningham | Director | – | Apr 29, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Peter Ashley Marks Director | Aug 31, 2026 | Buy | +47,620 | $0.50 | $23.81K | 191,340 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Alterity Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 13,000 shares on Oct 2, 2026 over the last 90 days.
See a number that looks wrong?